​

Harmony Biosciences (HRMY) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

HRMY Stock Forecast

Harmony Biosciences (HRMY) stock forecast, based on 13 Wall Street analysts, predicts a 12-month average price target of $48.50, with a high of $70.00 and a low of $34.00. This represents a 16.53% increase from the last price of $41.62.

$25 $34 $43 $52 $61 $70 High: $70 Avg: $48.5 Low: $34 Last Closed Price: $41.62

HRMY Stock Rating

Harmony Biosciences stock's rating consensus is Buy, based on 13 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (61.54%), 3 Hold (23.08%), 2 Sell (15.38%), and 0 Strong Sell (0.00%).

Buy
Total 13 0 2 3 8 Strong Sell Sell Hold Buy Strong Buy

HRMY Price Target Upside V Benchmarks

TypeNameUpside
StockHarmony Biosciences16.53%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts1716
Avg Price Target$60.00$46.71$46.31
Last Closing Price$41.62$41.62$41.62
Upside/Downside44.16%12.23%11.27%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 26253-111
Aug, 26243-110
Jul, 26244-111
Jun, 26244-111
May, 26244-111
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 26, 2026Rudy LiWolfe Research$60.00$38.9554.04%44.16%
Aug 05, 2026Deutsche Bank$39.00$38.451.43%-6.30%
Aug 05, 2026Danielle BrillTruist Financial$34.00$39.28-13.44%-18.31%
Aug 05, 2026UBS$37.00$38.78-4.59%-11.10%
Aug 04, 2026Andreas ArgyridesOppenheimer$70.00$38.7880.51%68.19%
Aug 03, 2026Mizuho Securities$51.00$35.2444.72%22.54%
Jun 30, 2026David HoangDeutsche Bank$36.00$36.22-0.61%-13.50%
Feb 23, 2026Deutsche Bank$31.00$29.166.31%-25.52%
Feb 19, 2026Mizuho Securities$50.00$35.2841.72%20.13%
Feb 11, 2026Youn ShimUBS$46.00$37.9321.28%10.52%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 26, 2026Wolfe ResearchOutperforminitialise
Aug 05, 2026Deutsche BankHoldHoldhold
Aug 05, 2026UBSNeutralNeutralhold
Aug 04, 2026OppenheimerOutperformOutperformhold
Jul 20, 2026H.C. WainwrightBuyBuyhold
Jun 30, 2026Deutsche BankHoldHoldhold
Jun 24, 2026H.C. WainwrightBuyBuyhold
May 22, 2026H.C. WainwrightBuyBuyhold
Feb 23, 2026Deutsche BankBuyHolddowngrade
Feb 11, 2026UBSBuyNeutraldowngrade

Financial Forecast

EPS Forecast

$0 $3 $6 $9 $12 $15 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.60$3.07$2.17$2.56$2.76---
Avg Forecast$0.64$2.79$2.42$2.35$3.34$4.68$6.61$11.05
High Forecast$0.66$2.92$2.46$2.54$3.99$6.02$10.42$11.50
Low Forecast$0.62$2.63$2.38$2.07$2.01$3.15$4.68$10.66
Surprise %-6.25%10.04%-10.33%8.94%-17.37%---

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$305.44M$437.86M$582.02M$714.73M$868.45M---
Avg Forecast$303.77M$436.79M$582.76M$713.65M$852.00M$1.05B$1.31B$1.83B
High Forecast$311.41M$452.88M$583.40M$713.68M$876.86M$1.05B$1.35B$1.89B
Low Forecast$294.91M$418.27M$582.11M$713.61M$827.13M$1.05B$1.27B$1.78B
Surprise %0.55%0.24%-0.13%0.15%1.93%---

Net Income Forecast

$0 $140M $280M $420M $560M $700M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$34.60M$181.47M$128.85M$145.49M$158.69M---
Avg Forecast$121.44M$58.46M$128.85M$139.23M$206.35M$281.05M$390.23M$667.32M
High Forecast$149.49M$74.29M$163.31M$153.53M$240.96M$363.44M$629.08M$694.25M
Low Forecast$93.40M$42.64M$94.40M$124.93M$121.42M$190.17M$282.54M$643.53M
Surprise %-71.51%210.39%-4.50%-23.10%---

HRMY Forecast FAQ

Is Harmony Biosciences stock a buy?

Harmony Biosciences stock has a consensus rating of Buy, based on 13 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 3 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Harmony Biosciences is a favorable investment for most analysts.

What is Harmony Biosciences's price target?

Harmony Biosciences's price target, set by 13 Wall Street analysts, averages $48.5 over the next 12 months. The price target range spans from $34 at the low end to $70 at the high end, suggesting a potential 16.53% change from the previous closing price of $41.62.

How does Harmony Biosciences stock forecast compare to its benchmarks?

Harmony Biosciences's stock forecast shows a 16.53% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Harmony Biosciences over the past three months?

  • September 2026: 18.18% Strong Buy, 45.45% Buy, 27.27% Hold, 0% Sell, 9.09% Strong Sell.
  • August 2026: 20.00% Strong Buy, 40.00% Buy, 30.00% Hold, 0% Sell, 10.00% Strong Sell.
  • July 2026: 18.18% Strong Buy, 36.36% Buy, 36.36% Hold, 0% Sell, 9.09% Strong Sell.

What is Harmony Biosciences’s EPS forecast?

Harmony Biosciences's average annual EPS forecast for its fiscal year ending in December 2026 is $4.68, marking a 69.57% increase from the reported $2.76 in 2025. Estimates for the following years are $6.61 in 2027, and $11.05 in 2028.

What is Harmony Biosciences’s revenue forecast?

Harmony Biosciences's average annual revenue forecast for its fiscal year ending in December 2026 is $1.05B, reflecting a 20.65% increase from the reported $868.45M in 2025. The forecast for 2027 is $1.31B, and $1.83B for 2028.

What is Harmony Biosciences’s net income forecast?

Harmony Biosciences's net income forecast for the fiscal year ending in December 2026 stands at $281.05M, representing an 77.11% increase from the reported $158.69M in 2025. Projections indicate $390.22M in 2027, and $667.32M in 2028.